Self-amplifying RNA vaccine, delivered by cationic nanocarrier (LION™) elicits neutralizing antibody responses in mice and nonhuman primates and protects mice from enterovirus D68 (EV-D68) respiratory infection and resulting disease in mice. Findings published in the...

SEATTLE, Nov. 16, 2023 /PRNewswire/ -- HDT Bio Corp., a clinical-stage private company developing advanced RNA products to treat and prevent infectious diseases and cancer, today announced its participation at the World Vaccine Congress West Coast 2023 in Santa Clara,...

SEATTLE, Oct. 31, 2023 /PRNewswire/ -- HDT Bio Corp., a clinical-stage private company developing advanced RNA products to treat and prevent infectious diseases and cancer, today announced that Dr. Steven Reed, Chief Executive Officer of HDT Bio, will present at the...

Award will fund the development of HDT-201, HDT Bio's thermo-stable and broad-spectrum intranasal RIG-I Agonist RNA SARS-CoV-2 antiviral candidate HDT-201 investigated as pre-exposure or post exposure prophylactic in high-risk situations SEATTLE, Oct. 4, 2023...

Scientific Advisors to provide expertise and counsel on the clinical development of its RNA-based oncology pipeline candidates HDT Bio announces esteemed medical experts Dr. Charles Cobbs of the Swedish Neuroscience Institute and Dr. Elizabeth Jaffee of Johns Hopkins...

LION™-formulated repRNA vaccination exhibited a significant safety profile, along with enhanced efficacy and biodistribution response when compared to lipid nanoparticle (LNP)-formulated repRNA vaccines in mice Study findings, published in the peer-reviewed...

LION-formulated, repRNA vaccination against HIV-1 and ZIKV successfully produced a robust immunological response in pregnant rabbits; maternal antibodies were transferred in utero to newborn kits Findings published in the peer-reviewed journal Molecular Therapy...

Goal ‘to change the cancer research narrative in Africa’ by applying HDT Bio’s advanced technology to help reduce inequalities in health care PRETORIA, SOUTH AFRICA and SEATTLE, WA (January 30, 2023) – HDT Bio Corp., a developer of immunotherapies for infectious...

UTMB will collaborate with HDT Bio Corp. and the National Institute of Allergy and Infectious Diseases’ Rocky Mountain Labs to develop vaccines against Crimean-Congo hemorrhagic fever virus (CCHFV) and Nipah virus (NiV) The 5-year $59M prototype project will develop...